SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBTâ€, or the â€œCompanyâ€) via GBT Tokenize Corp (â€œGBT/Tokenizeâ€) , has started a series of improvements for its qTerm device as preparations for FDA certification process. The series of improvements are targeting higher measurements accuracy, reliability and compatibility with a broad spectrum of userâ€™s usage behavior. qTerm is aimed to measure human vitals with a touch of a finger. Based on prototype testing, debugging and study, conclusions were made in order to increase the deviceâ€™s accuracy and stability as expected pre-requisites towards the companyâ€™s intentions to file for FDA certification. There is no guarantee that the company or GBT/Tokenize will receive FDA certification for the qTerm.
qTerm first release will include body temperature, blood oxygen and heart rate vitals. The next release is planned to include blood pressure measurement. In order to increase consistency with userâ€™s measurement habits, the deviceâ€™s sensors will be re-located to more efficient positions to enable best and consistent results. For example, different users may press their finger using different pressure, and position. The body heat sensorâ€™s accuracy is highly dependent on its distance from the fingerâ€™s skin. A new location of the IR (Infra-Red) sensor will be defined to enable an optimum distance to accommodate different userâ€™s pressing pressure and position. The heart rate and SPO2 (Blood Oxygen) sensor needs a direct skin contact again with proper adjustments to different userâ€™s fingerâ€™s pressure, position and stability. An additional microchip will be installed to provide an expert algorithm to support broad userâ€™s measuring habits, compensating for different inputs, and providing a consistent results for heart rate and blood oxygen data. The device will be accompanied by a smartphone app and synchronized web application to keep a history and provide analytics for user’s records. It is the goal for the web application to provide a geographical location and proximity alert to assist with potential health risks. The series of modifications are done as preparations for an FDA certification to classify qTerm as a medical device to be marketed and sold in the US. The certification process is also aimed to define the device for telemedicine purposes enabling remote vitals results to be sent to clinics and hospitals for physicians review in real time.
“We believe these changes will significantly increase the deviceâ€™s performance, accuracy, and consistency we are required to meet during the FDA certification. We believe these changes will ensure the product’s safety, accuracy, and reliability along with high quality and efficiency. This technology, assuming we receive FDA certification of which there is no guarantee, is planned to be marketed and sold for personal and clinics usage also targeting it for the telemedicine arena. Another aspect is the deviceâ€™s planned Artificial Intelligence technology that will be offering advanced features like real-time health statistics, analytics, monitoring and real time, geographically proximity alert to assist with avoiding health risks. The modifications also are focus on human engineering aspect in order to ensure easier usability for the vitals measurements like fingerâ€™s position pointers and physical fingerâ€™s location structural design. We put extra emphasis on making the device easy for use, mainly intuitive. Vitals results can be crucial indicators to assist with early detection of illness and we are working to improve the deviceâ€™s performance and capabilities as preparations efforts for FDA clearance. It is in our R&D culture to constantly improve our technology in efforts to bring it to the highest standards and regulations, particularly in the medicine domain when it can save lives.” Said Danny Rittman GBT/Tokenize and the Companyâ€™s CTO.
GBT Technologies, Inc. (OTC PINK: GTCH) (â€œGBTâ€) ( http://gbtti.com ) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBTâ€™s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBTâ€™s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBTâ€™s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.
Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Companyâ€™s ability to raise capital on acceptable terms, if at all, the Companyâ€™s successful development of its products and the integration into its existing products and the commercial acceptance of the Companyâ€™s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
Dr. Danny Rittman, CTO
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of GBT Technologies Inc (GTCH) and does not buy, sell, or trade any shares of (GTCH). This article does not provide a professional analysis of a (GTCH) financial position. (GTCH) financial position and all other information regarding the featured Company should be verified directly with (GTCH). Please read our full disclaimer for more detailed information.